Search results
Results from the WOW.Com Content Network
Bristol Myers (BMY) gets FDA approval for the Opdivo and Yervoy combination for the treatment of HCC.
Nivolumab, sold under the brand name Opdivo, is an anti-cancer medication used to treat a number of types of cancer. [2] This includes melanoma, lung cancer, malignant pleural mesothelioma, renal cell carcinoma, Hodgkin lymphoma, head and neck cancer, urothelial carcinoma, colon cancer, esophageal squamous cell carcinoma, liver cancer, gastric cancer, and esophageal or gastroesophageal ...
Opdivo plus Yervoy is already approved to treat cancers of the skin, lung, kidney, colon and esophagus. The combination is also used to treat HCC patients who have been given Nexavar.
Bristol Myers (BMY) secures an FDA approval for two Opdivo-based regimens as the first-line treatment of unresectable advanced or metastatic esophageal squamous cell carcinoma.
Ipilimumab was approved by the U.S. Food and Drug Administration (FDA) in March 2011, to treat people with late-stage melanoma that has spread or cannot be removed by surgery. [ 8 ] [ 11 ] [ 20 ] [ 21 ] [ 22 ] It was later approved by the US FDA on October 28, 2015, for stage 3 patients as adjuvant therapy . [ 23 ]
The FDA accepts Bristol-Myers' (BMY) sBLA for the Opdivo-Yervoy combo for the first-line treatment of patients with metastatic or recurrent NSCLC with no EGFR or ALK genomic tumor aberrations.
Nivolumab/hyaluronidase, sold under the brand name Opdivo Qvantig, is a fixed-dose combination anti-cancer medication used for the treatment of various forms of cancer. [ 1 ] [ 2 ] Nivolumab/hyaluronidase contains nivolumab , a programmed death receptor-1 (PD-1)-blocking monoclonal antibody ; and hyaluronidase , an endoglycosidase . [ 1 ]
(Reuters) -The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers Squibb's blockbuster cancer drug, Opdivo. Opdivo is part of a class of ...